Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OSMITROL 20% IN WATER IN PLASTIC CONTAINER vs MANNITOL 10%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into extracellular fluid and increasing renal tubular osmotic pressure, thereby inhibiting water reabsorption and promoting diuresis.
Mannitol is an osmotic diuretic that increases urinary output by raising the osmolarity of glomerular filtrate, thereby reducing tubular reabsorption of water and solutes. It also reduces cerebral edema by creating an osmotic gradient across the blood-brain barrier, drawing water from brain tissue into plasma.
Reduction of intracranial pressure and cerebral edema,Reduction of intraocular pressure when administered intravenously,Promotion of diuresis in the prevention of acute renal failure,Diagnostic aid for renal function measurement
Reduction of intracranial pressure and cerebral edema,Promotion of diuresis in patients with acute renal failure (oliguric phase) or to prevent renal failure in certain conditions,Reduction of intraocular pressure in acute glaucoma,Enhancement of urinary excretion of toxic substances (e.g., in overdoses),Adjunct in dialysis or hemofiltration (off-label)
0.25-1 g/kg intravenously over 30-60 minutes, repeated every 6-12 hours if needed.
0.25-2 g/kg intravenously as a 10% solution over 30-60 minutes, typically 50-100 g every 6-8 hours.
Terminal elimination half-life is 0.25–1.5 hours in normal renal function; prolonged to 4–6 hours with anuria or oliguria. Clinically, osmotic diuresis lasts as long as urine output sustains concentration.
Terminal half-life: 1.1–1.6 hours; prolonged to 6–36 hours in renal impairment
Not significantly metabolized; excreted unchanged by the kidneys via glomerular filtration.
Mannitol is not metabolized in the body. It is eliminated unchanged by the kidneys via glomerular filtration with minimal tubular reabsorption.
Primarily renal (90-100% unchanged) via glomerular filtration; <3% metabolized in liver; minimal biliary/fecal excretion.
Renal: 90% as unchanged drug; <10% metabolized in liver to fructose and glucose; fecal: negligible
Approximately 0%; no significant protein binding.
Negligible (<2%); does not bind to plasma proteins
0.3–0.6 L/kg; distributes primarily in extracellular fluid, limited intracellular penetration. Higher Vd in edema states.
0.36–0.5 L/kg; distributes primarily in extracellular fluid, limited CNS penetration due to hydrophilic nature
Intravenous: 100% (only route of administration); oral bioavailability is negligible due to poor absorption and osmotic diarrhea.
IV: 100%; oral: negligible (<10%) due to poor absorption and osmotic diarrhea
Contraindicated in anuria; for oliguria, monitor urine output closely; no specific GFR-based dose adjustment established, but use with caution in renal impairment.
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). For GFR 20-50 m L/min, reduce dose by 50% and monitor serum osmolality.
No specific Child-Pugh based adjustment; use with caution in hepatic failure.
No specific Child-Pugh based adjustment required; use with caution in severe hepatic impairment due to risk of fluid overload.
0.25-1 g/kg intravenously over 30-60 minutes, repeat every 4-6 hours as needed; maximum 2 g/kg/day.
0.25-1 g/kg intravenously as a 10% solution over 30-60 minutes, repeated every 6-8 hours as needed.
Start at lower end of dosing range (0.25 g/kg) due to decreased renal function; monitor electrolytes and renal function closely.
Start at lower end of dosing range (0.25-0.5 g/kg) due to decreased renal function; monitor fluid and electrolyte balance closely.
May cause osmotic nephrosis and acute renal failure, especially with doses >200 g or in patients with pre-existing renal disease.
None
Monitor serum electrolytes, osmolarity, and renal function,Avoid extravasation as it may cause tissue necrosis,Use with caution in patients with cardiac or pulmonary congestion,May precipitate heart failure due to volume expansion
Use with caution in patients with congestive heart failure due to risk of pulmonary edema from fluid overload,Monitor serum electrolytes (especially sodium and potassium) and renal function during therapy,May cause acute kidney injury with excessive doses or pre-existing renal impairment,In patients with intracranial hemorrhage, avoid rapid reduction of intracranial pressure,May cause expansion of extracellular fluid volume leading to pulmonary edema in patients with compromised cardiac function
Anuria due to severe renal disease,Severe pulmonary congestion or edema,Active intracranial bleeding (except during craniotomy),Severe dehydration,Hypersensitivity to mannitol
Anuria due to severe renal disease,Severe pulmonary edema or congestion,Active intracranial bleeding (except during craniotomy),Severe dehydration,Hypersensitivity to mannitol
No specific food interactions. Maintain adequate hydration as directed. Patients with electrolyte imbalances may require dietary modifications (e.g., sodium or potassium adjustments) based on serum levels. Avoid excessive fluid intake unless instructed, as it may counteract the osmotic effect.
Avoid high-sodium foods and salt substitutes to prevent electrolyte imbalance; maintain adequate fluid intake unless fluid restriction is advised; no specific food interactions, but monitor for changes in blood glucose if diabetic.
Pregnancy Category C. Animal reproduction studies have not been conducted. Osmotic diuretics may cause maternal dehydration and electrolyte imbalances. Inadequate human data across all trimesters; potential fetal harm if maternal hypovolemia or severe electrolyte disturbances occur. Use only if clearly needed.
Mannitol is a pregnancy category C drug. First trimester: Limited human data; animal studies indicate potential for fetal harm at high doses due to osmotic effects, but risk with clinical use is low. Second trimester: Generally safe for short-term use when indicated (e.g., elevated intracranial pressure), but avoid prolonged exposure to prevent fetal dehydration or electrolyte imbalances. Third trimester: Use cautiously; osmotic diuresis may cause maternal hypovolemia, potentially reducing placental perfusion and leading to fetal distress.
Excretion in human milk unknown. Avoid breastfeeding during administration due to potential for adverse effects in infant (e.g., electrolyte imbalance, dehydration). M/P ratio is not available.
Mannitol is excreted into breast milk in low concentrations (estimated M/P ratio <0.1) due to its high molecular weight and hydrophilicity. Oral bioavailability in infants is negligible, and no adverse effects have been reported. However, caution is advised if used repeatedly or in high doses, as theoretical risk of neonatal electrolyte imbalance exists.
No established dose adjustments specific to pregnancy. Monitor for increased plasma volume and reduced serum osmolality in pregnancy; adjust dose to avoid overcorrection or depletion. Titrate based on clinical response and laboratory values.
Pregnancy does not significantly alter the pharmacokinetics of mannitol. Standard adult dosing (0.25–2 g/kg as a 10% solution) is recommended, with adjustments based on renal function, volume status, and therapeutic response. Avoid excessive doses to prevent maternal volume overload and electrolyte disturbances.
Osmotrol 20% (mannitol) is a hyperosmotic agent used to reduce intracranial pressure (ICP) and cerebral edema. Administer via IV infusion using an in-line filter (pore size ≤5 microns) to prevent mannitol crystals from entering the circulation. Monitor serum osmolality closely; target <320 m Osm/L to avoid acute kidney injury. Rapid administration can cause transient hypervolemia, which may precipitate heart failure in susceptible patients. Onset of action typically within 15–30 minutes for ICP reduction. Extravasation risk: mannitol causes venous irritation; stop infusion immediately if pain or swelling occurs.
Administer via in-line filter to prevent crystallization; monitor serum sodium and osmolality closely to avoid hypernatremia and osmotic demyelination; ensure adequate urine output before use to avoid pulmonary edema; use with caution in patients with congestive heart failure or renal impairment; can cause transient volume expansion followed by diuresis.
This medication is given through a vein to reduce swelling in the brain or to promote urine output.,Report any burning, pain, or redness at the IV site immediately.,You may experience increased thirst or a dry mouth during treatment.,Kidney function and blood levels will be monitored regularly while receiving this medication.,If you have a history of heart failure or kidney problems, inform your healthcare provider.,Do not drive or operate machinery if you feel dizzy or faint.,Tell your doctor about all other medications you are taking, especially diuretics or medications that affect kidney function.
This medication may cause increased thirst and frequent urination.,Report any chest pain, difficulty breathing, or swelling of ankles/legs.,Avoid consuming salty foods to prevent fluid retention.,Do not stop taking without consulting your doctor.,Inform your doctor if you have kidney disease, heart failure, or are on a low-salt diet.
No interactions on record
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OSMITROL 20% IN WATER IN PLASTIC CONTAINER vs MANNITOL 10%, answered by our medical review team.
OSMITROL 20% IN WATER IN PLASTIC CONTAINER is a Osmotic Diuretic that works by Osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into extracellular fluid and increasing renal tubular osmotic pressure, thereby inhibiting water reabsorption and promoting diuresis.. MANNITOL 10% is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases urinary output by raising the osmolarity of glomerular filtrate, thereby reducing tubular reabsorption of water and solutes. It also reduces cerebral edema by creating an osmotic gradient across the blood-brain barrier, drawing water from brain tissue into plasma.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OSMITROL 20% IN WATER IN PLASTIC CONTAINER and MANNITOL 10% depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OSMITROL 20% IN WATER IN PLASTIC CONTAINER is: 0.25-1 g/kg intravenously over 30-60 minutes, repeated every 6-12 hours if needed.. The standard adult dose of MANNITOL 10% is: 0.25-2 g/kg intravenously as a 10% solution over 30-60 minutes, typically 50-100 g every 6-8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OSMITROL 20% IN WATER IN PLASTIC CONTAINER and MANNITOL 10% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OSMITROL 20% IN WATER IN PLASTIC CONTAINER is classified as Category C. Pregnancy Category C. Animal reproduction studies have not been conducted. Osmotic diuretics may cause maternal dehydration and electrolyte imbalances. Inadequate human data across. MANNITOL 10% is classified as Category A/B. Mannitol is a pregnancy category C drug. First trimester: Limited human data; animal studies indicate potential for fetal harm at high doses due to osmotic effects, but risk with c. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.